Kanagasabay R R, Unsworth-White M J, Robinson G, Bevan D, Farnsworth G, Haxby E J, Smith E E
Department of Cardiothoracic Surgery, St George's Hospital, London, England.
Ann Thorac Surg. 1998 Aug;66(2):567-9. doi: 10.1016/s0003-4975(98)00511-6.
Heparin is the standard anticoagulant for patients undergoing cardiopulmonary bypass. There are some patients for whom heparin is unsuitable and ancrod (a defibrinogenating enzyme) has been used as an alternative. We present a patient with heparin-induced thrombocytopenia in whom treatment ancrod was ineffective. The addition of danaparoid sodium (a heparinoid) allowed safe cardiopulmonary bypass. We discuss the reasons for this and suggest that the combination of ancrod and danaparoid sodium is a logical one in such cases.
肝素是接受体外循环患者的标准抗凝剂。有一些患者不适合使用肝素，于是使用了抗栓酶（一种去纤维蛋白原酶）作为替代。我们报告了一名肝素诱导的血小板减少症患者，抗栓酶治疗对其无效。添加达那肝素钠（一种类肝素）使体外循环得以安全进行。我们讨论了其中的原因，并建议在这种情况下，抗栓酶与达那肝素钠联合使用是合理的。
